FORTRESS BIOTECH INC - FBIO 9 3/8 PERP(NASDAQ:FBIOP) stock Fundamental Analysis

Fundamental Rating

FBIOP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. Both the profitability and financial health of FBIOP have multiple concerns. FBIOP is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year FBIOP has reported negative net income.

In the past year FBIOP has reported a negative cash flow from operations.

In the past 5 years FBIOP always reported negative net income.

FBIOP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

FBIOP has a Return On Assets of -38.75%. This is comparable to the rest of the industry: FBIOP outperforms 57.24% of its industry peers.

The Return On Equity of FBIOP (-245.82%) is worse than 72.26% of its industry peers.

		Industry Rank	Sector Rank
ROA	-38.75%
ROE	-245.82%
ROIC	N/A

ROA(3y)-36.39%

ROA(5y)-27.89%

ROE(3y)-252.68%

ROE(5y)-172.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 63.80%, FBIOP is in the better half of the industry, outperforming 78.80% of the companies in the same industry.

FBIOP's Gross Margin has declined in the last couple of years.

FBIOP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.8%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.13%

GM growth 5Y-2.19%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FBIOP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, FBIOP has more shares outstanding

Compared to 5 years ago, FBIOP has more shares outstanding

The debt/assets ratio for FBIOP is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -8.21, we must say that FBIOP is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -8.21, FBIOP is not doing good in the industry: 70.14% of the companies in the same industry are doing better.

FBIOP has a Debt/Equity ratio of 2.55. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of FBIOP (2.55) is worse than 82.51% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.55
Debt/FCF	N/A
Altman-Z	-8.21

ROIC/WACCN/A

WACC10.93%

2.3 Liquidity

FBIOP has a Current Ratio of 1.27. This is a normal value and indicates that FBIOP is financially healthy and should not expect problems in meeting its short term obligations.

FBIOP has a Current ratio of 1.27. This is amonst the worse of the industry: FBIOP underperforms 84.81% of its industry peers.

A Quick Ratio of 1.06 indicates that FBIOP should not have too much problems paying its short term obligations.

Looking at the Quick ratio, with a value of 1.06, FBIOP is doing worse than 86.40% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.27
Quick Ratio	1.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

FBIOP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.55%, which is quite impressive.

Looking at the last year, FBIOP shows a very negative growth in Revenue. The Revenue has decreased by -31.76% in the last year.

Measured over the past years, FBIOP shows a quite strong growth in Revenue. The Revenue has been growing by 9.50% on average per year.

EPS 1Y (TTM)63.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%41.41%

Revenue 1Y (TTM)-31.76%

Revenue growth 3Y-5.71%

Revenue growth 5Y9.5%

Sales Q2Q%-24.2%

3.2 Future

FBIOP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.90% yearly.

The Revenue is expected to grow by 64.44% on average over the next years. This is a very strong growth

EPS Next Y49.88%

EPS Next 2Y29.87%

EPS Next 3Y22.9%

EPS Next 5YN/A

Revenue Next Year56.79%

Revenue Next 2Y61.67%

Revenue Next 3Y50.04%

Revenue Next 5Y64.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBIOP. In the last year negative earnings were reported.

Also next year FBIOP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

FBIOP's earnings are expected to grow with 22.90% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y29.87%

EPS Next 3Y22.9%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

FBIOP has a Yearly Dividend Yield of 5.91%, which is a nice return.

Compared to an average industry Dividend Yield of 52.28, FBIOP pays a better dividend. On top of this FBIOP pays more dividend than 99.12% of the companies listed in the same industry.

Compared to an average S&P500 Dividend Yield of 2.44, FBIOP pays a better dividend.

		Industry Rank	Sector Rank
Dividend Yield	5.91%

5.2 History

The dividend of FBIOP decreases each year by -17.74%.

FBIOP has been paying a dividend for over 5 years, so it has already some track record.

The dividend of FBIOP decreased in the last 3 years.

Dividend Growth(5Y)-17.74%

Div Incr Years0

Div Non Decr Years2

5.3 Sustainability

FBIOP has negative earnings and hence a negative payout ratio. The dividend may be in danger.

DP-8.43%

EPS Next 2Y29.87%

EPS Next 3Y22.9%

More info and screens

Find the best dividend stocks

Show peers with best dividend

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP

NASDAQ:FBIOP (5/2/2025, 8:00:02 PM)

6.61

-0.02 (-0.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-31 2025-03-31/amc

Earnings (Next)05-13 2025-05-13/amc

Inst Owners17.31%

Inst Owner ChangeN/A

Ins Owners20.71%

Ins Owner ChangeN/A

Market Cap195.46M

Analysts82.22

Price Target63.58 (861.88%)

Short Float %0%

Short Ratio0.03

Dividend

		Industry Rank	Sector Rank
Dividend Yield	5.91%

Yearly Dividend0.22

Dividend Growth(5Y)-17.74%

DP-8.43%

Div Incr Years0

Div Non Decr Years2

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-11.42%

Min EPS beat(2)-25.23%

Max EPS beat(2)2.39%

EPS beat(4)3

Avg EPS beat(4)15.07%

Min EPS beat(4)-25.23%

Max EPS beat(4)41.63%

EPS beat(8)5

Avg EPS beat(8)20.17%

EPS beat(12)7

Avg EPS beat(12)13.83%

EPS beat(16)8

Avg EPS beat(16)-21.32%

Revenue beat(2)0

Avg Revenue beat(2)-32.26%

Min Revenue beat(2)-55.48%

Max Revenue beat(2)-9.04%

Revenue beat(4)0

Avg Revenue beat(4)-18.82%

Min Revenue beat(4)-55.48%

Max Revenue beat(4)-1.14%

Revenue beat(8)3

Avg Revenue beat(8)8.65%

Revenue beat(12)4

Avg Revenue beat(12)1.11%

Revenue beat(16)6

Avg Revenue beat(16)-2.1%

PT rev (1m)6.18%

PT rev (3m)8.22%

EPS NQ rev (1m)-312.5%

EPS NQ rev (3m)-312.5%

EPS NY rev (1m)-8.32%

EPS NY rev (3m)-8.32%

Revenue NQ rev (1m)-47.75%

Revenue NQ rev (3m)-47.75%

Revenue NY rev (1m)-31.42%

Revenue NY rev (3m)-31.42%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.38
P/FCF	N/A
P/OCF	N/A
P/B	8.58
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-3.27

EYN/A

EPS(NY)-1.64

Fwd EYN/A

FCF(TTM)-3.22

FCFYN/A

OCF(TTM)-2.72

OCFYN/A

SpS1.95

BVpS0.77

TBVpS-0.31

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-38.75%
ROE	-245.82%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	63.8%
FCFM	N/A

ROA(3y)-36.39%

ROA(5y)-27.89%

ROE(3y)-252.68%

ROE(5y)-172.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.13%

GM growth 5Y-2.19%

F-Score1

Asset Turnover0.4

Health

		Industry Rank	Sector Rank
Debt/Equity	2.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	336.02%
Cap/Sales	26.01%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.27
Quick Ratio	1.06
Altman-Z	-8.21

F-Score1

WACC10.93%

ROIC/WACCN/A

Cap/Depr(3y)152.42%

Cap/Depr(5y)127.86%

Cap/Sales(3y)11.86%

Cap/Sales(5y)9.94%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)63.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%41.41%

EPS Next Y49.88%

EPS Next 2Y29.87%

EPS Next 3Y22.9%

EPS Next 5YN/A

Revenue 1Y (TTM)-31.76%

Revenue growth 3Y-5.71%

Revenue growth 5Y9.5%

Sales Q2Q%-24.2%

Revenue Next Year56.79%

Revenue Next 2Y61.67%

Revenue Next 3Y50.04%

Revenue Next 5Y64.44%

EBIT growth 1Y20.18%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year62.35%

EBIT Next 3Y22.94%

EBIT Next 5YN/A

FCF growth 1Y28.58%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y37.46%

OCF growth 3YN/A

OCF growth 5YN/A

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens